ADBE enters its September 10 earnings date with the stock 27% lower year-to-date, yet up 11% over the past month — a recovery that looks more like a relief rally than a re-rating, given how divided the Street remains on the company's direction.
The most interesting signal this week comes from analyst activity, and it points in two directions at once. B of A Securities raised its price target on Tuesday to $220 from $190, but kept the Underperform rating — a move that acknowledges the stock has run but does nothing to change the bearish thesis. That sits in sharp contrast to Morgan Stanley's late-July downgrade to Underweight, where Keith Weiss cut his target from $365 to $240, a reduction that crystallised the leadership vacuum concern: both the CEO and CFO are departing, and the company has pivoted toward a freemium customer-acquisition model that the bears argue will structurally compress near-term revenue. The mean consensus target of $270.61 sits close to current price at $263.14, which looks less like a balanced view and more like a wide dispersion story — CLSA initiated at $300 Outperform in July while Goldman Sachs holds a Sell with a $190 target, a $110 gap that reflects genuine disagreement rather than fine-tuning. The analyst recommendation divergence factor scores in the 8th percentile — close to maximum bearishness relative to the broader universe.
Positioning in the lending market is firmly in the "not crowded" camp. Short interest runs at 4.6% of free float, down roughly 3% on the week and off nearly 2% over the past month — a slow bleed in bears rather than any fresh conviction. Borrow availability is extraordinarily loose at over 4,400% of short interest, meaning there are more than 44 shares available to lend for every one currently borrowed. Cost to borrow has ticked up 38% on the week to 0.44%, but that remains firmly in the low single digits. The short score of 38 is drifting down from 39 last week, consistent with the gradual unwind. Nothing in the lending picture flags a squeeze or a positioning extreme in either direction.
Options tell a mildly more cautious story, though not dramatically so. The put/call ratio runs at 0.60, roughly one standard deviation above its 20-day mean of 0.56. That's elevated relative to the recent norm, and the ratio has climbed steadily from near its 52-week low of 0.52 in early August — a gradual shift toward more hedging, rather than a sudden defensive spike. The 52-week high PCR of 0.99 shows just how much room remains before options positioning becomes genuinely alarmed.
Valuation is the other angle worth noting. The stock trades at a price-to-earnings multiple of 10x on the current reading, up roughly 0.9 turns over 30 days — reflecting the month's price recovery but still modest for a franchise of this quality. The EV/EBITDA multiple has actually compressed slightly over the same period to 7.9x. Those numbers look undemanding, which is precisely the bull case: CLSA's $300 target and PRIMECAP's continued accumulation (adding over one million shares as of April) suggest some large holders see the valuation as a floor.
Earnings history sharpens the risk framing. The June print saw the stock fall 12.6% on the day and 16.4% over the following five days — the combination of guidance cuts and executive departures landing harder than expected. With the next release on September 10, the question for the coming weeks is whether the month-long recovery in the stock has rebuilt enough goodwill among holders that another cautious guide triggers a smaller reaction — or whether the B of A and Goldman Sachs bears prove correct that the freemium pivot has yet to show up in the revenue line.
See the live data behind this article on ORTEX.
Open ADBE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
